April 2026
1. SHEN P, Wang X, Yan X, Du H, et al
   High RMI1 expression is associated with cancer cell progression and poor prognosis in prostate cancer.
   Oncol Rep. 2026;55:55.
   

   >> Share

   
   
2. LAKSHMI PSV, Parashar J, Biswas B, Ummanni R, et al
   Hypoxia?induced miR?135b?5p promotes neuroendocrine differentiation of prostate cancer cells through HIF1AN?HIF1alpha axis.
   Oncol Rep. 2026;55:74.
   

   >> Share

   
   November 2025
3. NAKAYAMA M, Takagi-Maeda S, Machino Y, Nihira K, et al
   Novel tetravalent bispecific antibody, PSMA/TRAIL?R2 REGULGENT, induces selective tumor cell apoptosis without hepatotoxicity.
   Oncol Rep. 2025;54:155.
   

   >> Share

   
   September 2025
4. WU S, Huang J, Hui K, Yue Y, et al
   [Corrigendum] 2'?Hydroxyflavanone inhibits epithelial?mesenchymal transition, and cell migration and invasion via suppression of the Wnt/beta?catenin signaling pathway in prostate cancer.
   Oncol Rep. 2025;54:102.
   

   >> Share

   
   
5. LI YF, Su S, Luo Y, Wei C, et al
   Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review).
   Oncol Rep. 2025;54:109.
   

   >> Share

   
   July 2025
6. LIU C, Tang Y, Wang J, Zhou Y, et al
   Effect of Polygonatum Sibiricum polysaccharides on nude mice model of prostate cancer PC?3 cells.
   Oncol Rep. 2025;54:84.
   

   >> Share

   
   April 2025
7. GUO X, Li S
   Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).
   Oncol Rep. 2025;53:46.
   

   >> Share

   
   February 2025
8. YANG C, Wang L, Gong C, Lv D, et al
   Antibody?drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review).
   Oncol Rep. 2025;53:21.
   

   >> Share

   
   November 2024
9. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
   [Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
   Oncol Rep. 2024;52:152.
   

   >> Share

   
   October 2024
10. NOURUZI S, Johnson F, Kumar S, Sivak O, et al
    Targeting adenocarcinoma and enzalutamide?resistant prostate cancer using the novel anti?androgen inhibitor ADA?308.
    Oncol Rep. 2024;52:132.
    

    >> Share

    
    June 2024
11. LIU Y, Qin Z, Yang K, Liu R, et al
    [Corrigendum] Cripto?1 promotes epithelial?mesenchymal transition in prostate cancer via Wnt/beta?catenin signaling.
    Oncol Rep. 2024;51:75.
    

    >> Share

    
    
12. PAN J, Tong F, Ren N, Ren L, et al
    Role of N(6)?methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).
    Oncol Rep. 2024;51:88.
    

    >> Share

    
    May 2024
13. HSIA YJ, Lin ZM, Zhang T, Chou TC, et al
    Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration?resistant prostate cancer cells.
    Oncol Rep. 2024;51:71.
    

    >> Share

    
    March 2024
14. PARAJULI KR, Jung Y, Taichman RS
    Abscisic acid signaling through LANCL2 and PPARgamma induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
    Oncol Rep. 2024;51:39.
    

    >> Share

    
    January 2024
15. LEE DY, Chun JN, So I, Jeon JH, et al
    Oncogenic role of FOXM1 in human prostate cancer (Review).
    Oncol Rep. 2024;51:15.
    

    >> Share

    
    December 2023
16. LEE DY, Lee S, Kim YS, Park S, et al
    Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK?dependent manner.
    Oncol Rep. 2023;50:218.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share